A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)

References

• ZostavaxTM (zoster vaccine. live) [package insert]. Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth (NJ, USA); 2009 2018 Mar 27 http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm132831.pdf.
   Google Scholar
• ZostavaxTM European Label. Merck Sharp & Dohme, Corp, a subsidiary of Merck & Co., Inc., Kenilworth (NJ, USA); 2017 [ 2018 Mar 27] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000674/WC500053462.pdf.
   Google Scholar
• European Medicines Agency, London, United Kingdom, ZostavaxTM; 2016 [ 2018 Mar 27] http://wwwemaeuropaeu/ema/indexjsp?curl=pages/medicines/human/medicines/000674/human_med_001185jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Center for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60(44):1528.
   PubMedGoogle Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–928. doi:10.1093/cid/cir970.
   PubMed Web of Science ®Google Scholar
• Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51(2):197–213. doi:10.1086/653605.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284. doi:10.1056/NEJMoa051016.
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152(9):545–554. doi:10.7326/0003-4819-152-9-201005040-00004.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventitive vaccine clinical trials; 2007 [accessed 2018 Mar 27]. https://wwwfdagov/downloads/BiologicsBloodVaccines/ucm091977.
   Google Scholar
• Arakane R, Nakatani H, Fujisaki E, Takahama A, Ishida K, Yoshiike M, Nakayama T, Takeshita F. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial. Vaccine. 2015;33(46):6340–6350. doi:10.1016/j.vaccine.2015.09.010.
   PubMed Web of Science ®Google Scholar
• S Ga B, Sapru A, Mitra M, Chatterjee S, Bhattacharya N, Kadhe G, Mane A, Roy S. Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-ATM) in healthy Indian children. Vaccine: Dev Ther. 2013;2014(4):1–6.
   Google Scholar
• W Cj C, Choi J, Eom J, Kim S, Pai H, Peck K, Sohn J, Cheong H. Immunogenicity and safety of a live attenuated zoster vaccine (ZostavaxTM) in Korean adults. J Korean Med Sci. 2016;31:13–17. doi:10.3346/jkms.2016.31.1.13.
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Weinke T, Garcia De Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged >/=50 years: a randomised non-inferiority clinical trial. Vaccine. 2015;33(6):789–795. doi:10.1016/j.vaccine.2014.12.024.
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39(3):342–348. doi:10.1086/421942.
   PubMed Web of Science ®Google Scholar
• Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS, Annunziato PW, Parrino J. Safety and tolerability of zoster vaccine in adults >/=60 years old. Hum Vaccin. 2011;7(11):1130–1136. doi:10.4161/hv.7.11.17982.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a vaccine safety datalink study. J Intern Med. 2012;271(5):510–520. doi:10.1111/j.1365-2796.2011.02474.x.
   PubMed Web of Science ®Google Scholar
• Baxter R, Tran TN, Hansen J, Emery M, Fireman B, Bartlett J, Lewis N, Saddier P. Safety of zostavax–a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–6641. doi:10.1016/j.vaccine.2012.08.070.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;208(4):559–563. doi:10.1093/infdis/jit182.
   PubMed Web of Science ®Google Scholar
• Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Vaccine. 2017;35(52):7231–7239. doi:10.1016/j.vaccine.2017.11.013.
   PubMed Web of Science ®Google Scholar
• Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, Heininger U, Loupi E, Marcy SM. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in patient safety: from research to implementation (volume 2: concepts and methodology). Rockville: Agency for Healthcare Research & Quality (US); Pub No.: 05-0021-2. (MD); 2005.
   Google Scholar
• Coplan P, Chiacchierini L, Nikas A, Shea J, Baumritter A, Beutner K, Cassidy W, Sawyer M, Watson B, Heyse J, et al. Development and evaluation of a standardized questionnaire for identifying adverse events in vaccine clinical trials. Pharmacoepidemiol Drug Saf. 2000;9(6):457–471. doi:10.1002/1099-1557(200011)9:6<457::AID-PDS529>3.0.CO;2-R.
   PubMed Web of Science ®Google Scholar
• Norquist JM, Khawaja SS, Kurian C, Mast TC, Liaw KL, Robertson MN, Evans B, Gutsch D, Saddier P. Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance. Hum Vaccin Immunother. 2012;8(9):1208–1212. doi:10.4161/hv.21408.
   PubMed Web of Science ®Google Scholar